Advertisement


Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Advertisement